title: Sumatriptan suppositories for the acute treatment of migraine. S2B351 Study Group.
abstract: A randomised, double-blind, parallel-group, placebo-controlled trial was undertaken to assess the efficacy and tolerability of the sumatriptan suppository in 184 patients with acute migraine. Patients used a sumatriptan suppository (12.5 mg or 25 mg) or placebo at home for the treatment of a moderate or severe migraine attack and those who experienced headache recurrence within 24 hours of dosing had the option to repeat the dose. By 2 hours post-dose, 68% of patients in the sumatriptan 25 mg group and 47% of patients in the sumatriptan 12.5 mg group compared with 25% of placebo patients achieved headache relief. Relief rates 2 hours post-dose for nausea, vomiting, photophobia and phonophobia were similar to those reported 2 hours post-dose for headache. Post hoc review of the recurrence data showed that administration of a second suppository was effective in alleviating recurrent headache in over 80% of the sumatriptan-treated patients experiencing recurrence. No serious or unusual adverse events were reported, and the pattern and incidence of adverse events did not vary as a function of dose. These data demonstrate that the sumatriptan suppository is a well-tolerated, effective treatment for the acute treatment of migraine pain and its associated symptoms.
authors.affiliation: Glaxo Wellcome, Research Triangle Park, North Carolina, NC 27709, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Tepper
authors.forename: A
authors.initials: A
authors.lastname: Cochran
authors.forename: S
authors.initials: S
authors.lastname: Hobbs
authors.forename: M
authors.initials: M
authors.lastname: Woessner
mesh_terms: D000285:Administration, Rectal; D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D013488:Suppositories; D014839:Vomiting / Q000139:chemically induced
chemical_list: D012702:Serotonin Antagonists; D013488:Suppositories; D018170:Sumatriptan